CNAO National Center of Oncological Hadrontherapy
13
10
10
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
7.7%
1 terminated/withdrawn out of 13 trials
66.7%
-19.8% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Effect of Prehabilitation on Head and Neck Cancer Patients
Role: collaborator
Innovative SolutIons for DosimEtry in Hadrontherapy (INSIDE)
Role: lead
Longitudinal Registry Including Patients Treated With Heavy Particles
Role: lead
Clinical Study on the Re-irradiation of Lateral Pelvic Recurrences of Gynecological Malignancies
Role: lead
HRQoL in Patients With Solid Tumors Treated With Hadrontherapy
Role: lead
Sarcopenia in Head and Neck Cancer Patients Treated with Curative Hadrontherapy
Role: lead
Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma
Role: lead
Simultaneous Integrated Boost in Carbon Ion Radiotherapy for Head and Neck Adenoid Cystic Carcinoma
Role: lead
PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy
Role: collaborator
Multi-parametric Imaging in Personalized Radiotherapy
Role: lead
Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease
Role: lead
Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract
Role: lead
Proton Boost for Locally Advanced HEAD AND NECK TUMORS
Role: lead
All 13 trials loaded